Lundbeck Presentations & Investor Relations material

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disease areas such as depression, schizophrenia, Parkinson's disease and Alzheimer's disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the large treatment options, but there remains an unmet need for new and innovative therapeutics. We have more than 1,700 employees worldwide. We have more than 1,000 R&D and innovation centers in Denmark, China, China, China, China and other countries. We have